	US 12,071,454 B2
	Antigenic respiratory syncytial virus polypeptides
Gary J. Nabel, Bridgewater, NJ (US); Chih-Jen Wei, Bridgewater, NJ (US); Kurt Swanson, Bridgewater, NJ (US); Pradeep Dhal, Bridgewater, NJ (US); Ram Dharanipragada, Bridgewater, NJ (US); and Magnus Besev, Bridgewater, NJ (US)
Assigned to SANOFI, Paris (FR)
Filed by Sanofi, Paris (FR)
Filed on Oct. 1, 2020, as Appl. No. 17/061,065.
Application 17/061,065 is a continuation of application No. PCT/US2019/025387, filed on Apr. 2, 2019.
Claims priority of provisional application 62/652,199, filed on Apr. 3, 2018.
Prior Publication US 2021/0017237 A1, Jan. 21, 2021
Int. Cl. C07K 14/195 (2006.01)

CPC C07K 14/195 (2013.01) [C07K 2319/30 (2013.01)]

21 Claims

1. An antigenic respiratory syncytial virus (RSV) polypeptide comprising an RSV F polypeptide, wherein an asparagine of the RSV F polypeptide is glycosylated, thereby blocking an epitope of the RSV F polypeptide that is shared between pre-fusion RSV F and post-fusion RSV F, wherein the RSV F polypeptide comprises a sequence having at least 90% identity to amino acids 1-478 of SEQ ID NO: 23, and wherein the asparagine corresponds to position 288, 308, or 467 of SEQ ID NO: 23.